EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH COMPENSATED CIRRHOSIS AND EVIDENCE OF PORTAL HYPERTENSION DUE TO PRIMARY BILIARY CHOLANGITIS (PBC)

被引：0

作者：

Levy, Cynthia ^{[1
]}

Odin, Joseph ^{[2
]}

Neff, Guy W. ^{[3
]}

Trivedi, Palak ^{[4
,5
]}

Gheorghe, Liliana-Simona ^{[6
]}

Bowlus, Christopher L. ^{[7
]}

Vierling, John M. ^{[8
,9
]}

Gulamhusein, Aliya F. ^{[10
]}

Jeong, Sook-Hyang ^{[11
]}

Xu, Emily ^{[12
]}

Yang, Ke ^{[12
]}

Choi, Yun-Jung ^{[12
]}

Watkins, Elaine ^{[12
]}

McWherter, Charles ^{[12
]}

机构：

[1] Univ Miami, Coral Gables, FL 33124 USA

[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[3] Covenant Res & Clin LLC, Sarasota, FL USA

[4] Univ Birmingham, Natl Inst Hlth Res Birmingham Biomed Res Ctr, Birmingham, W Midlands, England

[5] Univ Birmingham, Ctr Liver & Gastrointestinal Res, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England

[6] Fundeni Clin Inst, Digest Dis & Liver Transplantat Ctr, Bucharest, Romania

[7] Univ Calif Davis, Sch Med, Div Gastroenterol & Hepatol, Davis, CA 95616 USA

[8] Baylor Coll Med, Dept Med, Houston, TX 77030 USA

[9] Baylor Coll Med, Dept Surg, Houston, TX 77030 USA

[10] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada

[11] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Internal Med, Seoul, South Korea

[12] Cymabay Therapeut, Newark, CA USA

来源：

HEPATOLOGY | 2021年 / 74卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1269

引用

页码：762A / 763A

页数：2

共 50 条

[1] Safety and Efficacy of Seladelpar in Primary Biliary Cholangitis Patients with Cirrhosis
Bowlus, Christopher L.
Hirschfield, Gideon
Bacon, Bruce R.
Galambos, Michael R.
Harrison, Stephen A.
Odin, Joseph
Amato, Gianni
Steinberg, Alexandra
Rosenbusch, Scott
Bergheanu, Sandrin
Boudes, Pol
HEPATOLOGY, 2018, 68 : 1077A - 1078A
[2] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies
Gordon, Stuart C.
Trivedi, Palak
Bowlus, Christopher
Michael, Galambos
Goel, Aparna
Gulamhusein, Aliya
Levy, Cynthia
Neff, Guy
Stanca, Carmen
Thorburn, Douglas
Bacon, Bruce
Borg, Brian
Doerffel, Yvonne
Forman, Lisa
Freilich, Bradley
Gheorghe, Liana
Gonzalez, Maria Sarai
Harrison, Stephen
Huang, Jonathan
Jeong, Sook-Hyang
Kim, Seung Up
Lake, John
Odin, Joseph
Tak, Won Young
Tobias, Hillel
Vierling, John M.
Yang, Ke
Steinberg, Alexandra
Choi, Yun-Jung
McWherter, Charles
Mayo, Marlyn J.
JOURNAL OF HEPATOLOGY, 2021, 75 : S686 - S687
[3] EFFICACY, SAFETY, AND TOLERABILITY OF SELADELPAR IN PATIENTS WITH COMPENSATED LIVER CIRRHOSIS DUE TO PRIMARY BILIARY CHOLANGITIS (PBC); A POOLED ANALYSIS OF PHASE 2 AND PHASE 3 STUDIES
Gordon, Stuart C.
Trivedi, Palak
Bowlus, Christopher L.
Galambos, Michael
Goel, Aparna
Gulamhusein, Aliya
Levy, Cynthia
Neff, Guy
Stanca, Carmen M.
Thorburn, Douglas
Bacon, Bruce R.
Borg, Brian B.
Doerffel, Yvonne
Forman, Lisa
Freilich, Bradley
Gheorghe, Liliana
Sarai Gonzalez-Huezo, Maria
Harrison, Stephen A.
Huang, Jonathan C.
Jeong, Sook-Hayng
Kim, Seung-Up
Lake, John
Odin, Joseph
Tak, Won Young
Tobias, Hillel
Vierling, John M.
Yang, Ke
Steinberg, Alexandra
Choi, Yun-Jung
Mcwherter, Charles A.
Mayo, Marlyn J.
GASTROENTEROLOGY, 2022, 162 (07) : S1191 - S1191
[4] EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND COMPENSATED CIRRHOSIS IN THE PHASE 3 PLACEBO-CONTROLLED RESPONSE TRIAL
Villamil, Alejandra
Younes, Ziad
Bowlus, Christopher
Vierling, John
Vasura, Adam
Galli, Andrea
Rabinovitz, Mordechai
Nevens, Frederik
Carroll, Susheela
Yang, Ke
Crittenden, Daria
McWherter, Charles
Lawitz, Eric
HEPATOLOGY, 2024, 80 : S517 - S518
[5] PHARMACOKINETICS OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS, WITH OR WITHOUT CIRRHOSIS
Mao, Lily
Bowlus, Christopher L.
Levy, Cynthia
Odin, Joseph
Stanca, Carmen M.
Trivedi, Palak
Varga, Monika
Bergheanu, Sandrin
Yang, Ke
Steinberg, Alexandra
Rossi, Stephen
Boudes, Pol
HEPATOLOGY, 2019, 70 : 807A - 808A
[6] Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis
Caines, Allyce
Trudeau, Sheri
Gordon, Stuart C.
EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (11) : 1517 - 1523
[7] The impact of portal hypertension in primary biliary cirrhosis (PBC)
Jones, DEJ
Walter, R
Prince, MI
Hudson, M
GUT, 2002, 50 : A118 - A119
[8] Efficacy and safety of seladelpar in patients with primary biliary cholangitis and compensated liver cirrhosis in the open-label, long-term ASSURE safety study: interim results
Gordon, Stuart C.
Jacobson, Ira
Younes, Ziad H.
Silveira, Marina
Drenth, Joost P. H.
Morgera, Ulrike
Dalekos, George
Heo, Jeong
Yang, Ke
Heusner, Carrie
Crittenden, Daria B.
McWherter, Charles A.
JOURNAL OF HEPATOLOGY, 2024, 80 : S20 - S20
[9] The prevalence of portal hypertension (PHT) in primary biliary cirrhosis (PBC)
Jones, DEJ
Walter, R
Prince, MI
Hudson, M
GUT, 2002, 50 : A113 - A113
[10] Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis and Compensated Liver Cirrhosis in the Open-Label, Long-Term ASSURE Safety Study: Interim Results
Gordon, Stuart C.
Jacobson, Ira
Younes, Ziad H.
Silveira, Marina
Drenth, Joost
Morgera, Ulrike
Dalekos, George
Heo, Jeong
Yang, Ke
Heusner, Carrie
Crittenden, Daria B.
Mcwherter, Charles A.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1217 - S1217

← 1 2 3 4 5 →